Business Wire

CA-HAI-ROBOTICS

22.3.2022 11:44:04 CET | Business Wire | Press release

Share
HAI ROBOTICS to Debut Cutting-edge ACR Systems in U.S. at MODEX 2022

HAI ROBOTICS , the pioneer in Autonomous Case-handling Robot (ACR) systems for warehouse logistics, will present its highly flexible totes-to-person warehouse automation solution at this year’s MODEX 2022 show, Booth C4585 at Georgia World Congress Center in Atlanta from March 28th to 31st.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005613/en/

With its robots being exhibited also by MHS, SVT Robotics, GreyOrange and Tompkins Robotics, the company will demonstrate alongside its strategic partners how its state-of-the-art warehousing technology complements the global supply chain.

Days ahead of MODEX 2022, HAI ROBOTICS announced new partnerships with Tompkins Robotics and Storage Solutions. The partnerships will see technology and solutions developed by HAI ROBOTICS being applied to various industries across North America.

Brian Reinhart, Vice President of Sales and Marketing at HAI ROBOTICS U.S., said the company would have a full display of its commitment to customers, partners and the U.S. market at the show after being in the market for over a year.

"It's a very exciting time for HAI ROBOTICS as we continue our expansion and growth in the U.S." he said. "In order to best serve the market and accommodate the requests of our end users, we are developing a robust, strong, and valuable partner network."

Reinhart, a veteran in the material-handling industry, says: "In a short time, we have planted deep roots in the U.S."

In addition to existing customers and partners, HAI ROBOTICS has established a U.S. HQ in Fremont, CA, a fully functional Demo Center with a decentralized sales and implementation strategy, positioning employees in 15 different states across the country.

The company's "ambitious goals have hiring, onboarding, and training of talented individuals as a top priority." "We want to be where our customers are to best serve them. We are committed to providing our partners with the best industry products, solutions, and service," he said.

Exhibits

The company's exhibits this year include two types of ACR robots and one workstation that were crafted to explore the full potentials of order-fulfillment efficiency, deployment flexibility and scalability in a goods-to-person order-handling context.

The HAIPICK A42T robot to be displayed is an evolution of the company’s IFOY 2021 "Best in Intralogistics" title earner. With a telescopic lift function that can flexibly adjust its picking height, it can handle bins (totes or cartons) at a storage height ranging from 0.28 to 10 meters.

It can carry 8 loads to feed goods-to-person workstations in one move, and shuttle between different storage areas without hindrance.

The HAIPICK A3 fork-lifting robot is a new invention that targets wider warehousing scenarios in addition to bin storage. It handles goods that don’t require a container, such as tires, trays and boards that can be lifted by a fork from the bottom. Its fork-lifting design brings an extra benefit of higher storage density, since spaces between neighboring bins can be reduced. This type of robot is a good match with working environments where control for dust, static and pollution is strict.

In addition to high flexibility, the HAIPICK robots outperform other goods-transporting robots by bringing every inch under the ceiling available for storage. However, it is the teamwork with the HAIPORT-powered Workstation that maximizes a warehouse’s throughput capacity.

A HAIPORT-powered Workstation , which can fulfill orders at in-bound and out-bound, involves collaboration between HAIPICK robots, HAIPORT and conveyor belts. HAIPORT is an automatic loading and unloading machine that can be docked with ACR robots and conveyor belts. At a HAIPORT-powered Workstation, multiple loads of totes or cartons are unloaded from the HAIPICK robots at the entry side of the HAIPORT, then transferred onto the conveyor belts for sorting per system orders and moved to the exit side of the HAIPORT, where they were fetched by robots for the next round of order processing.

The HAIPORT-powered Workstation is suitable for medium-to-large warehouses that have high throughput requirement of at least 400 bins per hour. It's machine rate can deliver 600 bins per hour to an operator. It suits for extensive storage scenarios in which medium and small-sized bins are used, such as raw materials, small electronics, apparel, medicine, retails and 3PL industries that have large number of SKUs.

ABOUT HAI ROBOTICS

HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse. The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.

Founded in 2016 in Shenzhen, China, HAI ROBOTICS has offices in the U.S., Europe, Japan, Southeast Asia, Hong Kong and Taiwan, serving customers from more than 30 countries and regions.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye